Harrison W. Farber, MD
Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, George Washington University



Dr. Farber is considered an opinion leader and internationally recognized expert in the field of pulmonary hypertension. He is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center.

Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury. He has extensive government and private funding and is an NIH-funded Principle Investigator on several grants. He is a member of several research groups both within the Pulmonary Center and in other divisions within the Department of Medicine: the Pulmonary Vascular Biology Group (Pulmonary Center); the Center for Excellence in Sickle Cell Disease (Hematology), the Scleroderma Vascular Disease Group (Rheumatology) and Pulmonary Vascular/Left Ventricular Study Group (Cardiology). Dr. Farber’s laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, with scleroderma, and with left ventricular diastolic dysfunction.

Dr. Farber's team is developing a database and registry of sickle cell patients with pulmonary hypertension (see Dr. Elizabeth Klings' faculty profile) as well as a database and registry of scleroderma patients with various forms of pulmonary disease including pulmonary hypertension. They are participating in numerous multi-center clinical trials of new therapies for pulmonary hypertension and have several single-site trials for novel proof of concept therapies for pulmonary hypertension.

2010 Robert Dawson Evans Special Recognition Teaching Award, Boston University School of Medicine


A Phase IV, Prospective, Single-Arm, Open-Label Study to measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
02/25/2015 - 02/24/2020 (PI)
Bayer HealthCare Pharmaceuticals


A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo Controlled Study of GS-4997 in subjects with Pulmonary Arterial Hypertension
12/22/2014 - 12/21/2019 (PI)
Gilead Sciences, Inc.


A 24-Week Pilot Study to Investigate Changes in Proteomic and Genomic Profiles in Patients with Pulmonary Arterial Hypertension Associated with Scleroderma Treated with Macitentan-PIONEER 2
11/05/2015 - 11/04/2019 (PI)
Actelion Pharmaceuticals, Ltd.


Uptravi® (SelexiPag): tHe usErs dRug rEgistry
09/01/2016 - 08/31/2018 (PI)
Actelion Pharmaceuticals US, Inc.


REPAIR: Right Ventricular Remodeling in Pulmonary Arterial Hypertension
07/15/2015 - 07/14/2018 (PI)
Actelion Pharmaceuticals, Ltd.


A Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca
06/11/2014 - 06/06/2018 (PI)
Actelion Clinical Operations, Inc.


A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Sympto
06/01/2012 - 05/31/2017 (PI)
Ikaria


A multi-Center, Double Blind, Placebo-Controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients with Pulmonary Hypertension
04/01/2011 - 05/31/2017 (PI)
Actelion Pharmaceuticals, Ltd.


EPOCH Treatment Satisfaction Qualitative Study (EPOCH-TSQS)
03/10/2015 - 03/09/2017 (PI)
Actelion Pharmaceuticals, Ltd.


National Biological Sample and Data Repository for PAH
03/01/2016 - 02/28/2017 (PI)
Cincinnati Children's Hospital Medical C NIH NHLBI
4R24HL105333-05

Showing 10 of 42 results. Show All Results



Yr Title Project-Sub Proj Pubs
2017 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 1R21AR069285-01A1
2015 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-05-7133 25
2014 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-04-7133 25
2013 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-03-7133 25
2012 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 5P50AR060780-02-7133 25
2011 Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and 1P50AR060780-01-7133 25
2007 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-05-2 78
2006 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-04 1
2006 Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome 5U54HL070819-04-2 78
2005 Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens 5R01HL068232-03 1
Showing 10 of 25 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2017 Oct 02. PMID: 29096938.
  2. Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulm Circ. 2017 Jul-Sep; 7(3):741-746. PMID: 28671485.
  3. Benza RL, Farber HW, Selej M, Gomberg-Maitland M. Assessing risk in pulmonary arterial hypertension: what we know, what we don''t. Eur Respir J. 2017 Aug; 50(2). PMID: 28775053.
  4. Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017 Mar 23; 9(1):27.View Related Profiles. PMID: 28330499; DOI: 10.1186/s13073-017-0417-1;.
  5. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016 Dec; 25(142):418-430. PMID: 27903664; DOI: 10.1183/16000617.0083-2016;.
  6. Sardana M, Moll M, Farber HW. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2016 Dec; 12(12):1513-1520. PMID: 27756196.
  7. Preston IR, Farber HW. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. J Thorac Dis. 2016 Sep; 8(9):E1106-E1107. PMID: 27747077.
  8. Finch KT, Stratton EA, Farber HW. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. J Heart Lung Transplant. 2016 Nov; 35(11):1370-1373. PMID: 27623099; DOI: 10.1016/j.healun.2016.07.015;.
  9. Cheong FY, Gower AC, Farber HW. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum. 2017 Feb; 46(4):465-472.View Related Profiles. PMID: 27499522; DOI: 10.1016/j.semarthrit.2016.05.015;.
  10. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation. 2016 May 17; 133(20):e662. PMID: 27185031; DOI: 10.1161/CIRCULATIONAHA.116.022321;.
Showing 10 of 200 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 200 publications over 37 distinct years, with a maximum of 15 publications in 2015

YearPublications
19801
19813
19822
19831
19853
19862
19875
19882
19892
19904
199110
19925
19936
19946
19955
19964
19977
19984
19996
20008
20018
20025
20036
20042
20058
20067
20072
20088
20098
201010
20117
20124
20139
20145
201515
20166
20174
Contact for Mentoring:


72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Farber's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department